CO2023010010A2 - Pharmaceutical composition comprising a diphenylpyrazine derivative - Google Patents

Pharmaceutical composition comprising a diphenylpyrazine derivative

Info

Publication number
CO2023010010A2
CO2023010010A2 CONC2023/0010010A CO2023010010A CO2023010010A2 CO 2023010010 A2 CO2023010010 A2 CO 2023010010A2 CO 2023010010 A CO2023010010 A CO 2023010010A CO 2023010010 A2 CO2023010010 A2 CO 2023010010A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
diphenylpyrazine derivative
diphenylpyrazine
derivative
diphenylpyrazin
Prior art date
Application number
CONC2023/0010010A
Other languages
Spanish (es)
Inventor
Wenyu Dong
Katie Amssoms
Proost Eddy De
Kok Paul Hartman
Rene Holm
Kristof Kimpe
Greet Meurs
Maxim Verstraeten
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CO2023010010A2 publication Critical patent/CO2023010010A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Abstract

La presente invención se relaciona con una composición farmacéutica que comprende calcio;{4-[(5,6-difenilpirazin-2-il)(propan-2-il)amino]butoxi}acetato, en particular a inyectables de acción prolongada que comprenden el mismo, el uso de la composición farmacéutica para el tratamiento o prevención de enfermedades específicas, y un proceso para producirlo.The present invention relates to a pharmaceutical composition comprising calcium;{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate, in particular to long-acting injectables comprising the same, the use of the pharmaceutical composition for the treatment or prevention of specific diseases, and a process for producing it.

CONC2023/0010010A 2021-01-29 2023-07-27 Pharmaceutical composition comprising a diphenylpyrazine derivative CO2023010010A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021052208 2021-01-29
EP2021082830 2021-11-24
PCT/EP2022/052073 WO2022162158A1 (en) 2021-01-29 2022-01-28 Pharmaceutical composition comprising a diphenylpyrazine derivative

Publications (1)

Publication Number Publication Date
CO2023010010A2 true CO2023010010A2 (en) 2023-08-09

Family

ID=80445780

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0010010A CO2023010010A2 (en) 2021-01-29 2023-07-27 Pharmaceutical composition comprising a diphenylpyrazine derivative

Country Status (11)

Country Link
US (1) US20240091223A1 (en)
EP (1) EP4284334A1 (en)
JP (1) JP2024508377A (en)
KR (1) KR20230137312A (en)
AU (1) AU2022214282A1 (en)
CA (1) CA3206133A1 (en)
CL (1) CL2023002216A1 (en)
CO (1) CO2023010010A2 (en)
IL (1) IL304525A (en)
TW (1) TW202239408A (en)
WO (1) WO2022162158A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2023238952A1 (en) * 2022-06-10 2023-12-14 日本新薬株式会社 Pharmaceutical composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (en) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
KR101581059B1 (en) 2008-02-28 2015-12-30 니뽄 신야쿠 가부시키가이샤 Fibrosis inhibitor
WO2009154246A1 (en) 2008-06-19 2009-12-23 日本新薬株式会社 Therapeutic agent for erectile dysfunction
SI2292231T1 (en) 2008-06-23 2016-03-31 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
WO2009157397A1 (en) 2008-06-23 2009-12-30 日本新薬株式会社 Therapeutic agent for intestinal tract injury accompanying administration of a non-steroid anti-inflammatory agent
ES2611483T3 (en) 2008-06-23 2017-05-09 Nippon Shinyaku Co., Ltd. Therapeutic agent for inflammatory bowel disease
PT2447254T (en) 2009-06-26 2018-01-04 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (en) 2009-08-26 2011-03-03 日本新薬株式会社 Base addition salts
JOP20190204A1 (en) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
WO2019023092A1 (en) 2017-07-24 2019-01-31 Pharmosa Biopharm Inc. Liposome compositions comprising weak acid drugs and uses thereof
US20210113464A1 (en) 2017-11-27 2021-04-22 Osaka University Disease-site-specific liposomal formulation
JP7032732B2 (en) 2018-03-01 2022-03-09 国立大学法人 東京大学 How to make platensimycin
WO2020249602A1 (en) * 2019-06-11 2020-12-17 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension

Also Published As

Publication number Publication date
KR20230137312A (en) 2023-10-04
TW202239408A (en) 2022-10-16
JP2024508377A (en) 2024-02-27
US20240091223A1 (en) 2024-03-21
EP4284334A1 (en) 2023-12-06
CA3206133A1 (en) 2022-08-04
AU2022214282A1 (en) 2023-08-10
CL2023002216A1 (en) 2024-03-01
IL304525A (en) 2023-09-01
WO2022162158A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
CO2023010010A2 (en) Pharmaceutical composition comprising a diphenylpyrazine derivative
PT1274698E (en) PERCYCININE, METHOD FOR PRODUCING AND USING IT AS A MEDICINAL PRODUCT
MX2021006421A (en) Amino-acid anilides as small molecule modulators of il-17.
ECSP034732A (en) DERIVATIVE OF PHENETHANOLAMINE FOR THE TREATMENT OF RESPIRATORY DISEASES
CL2008002394A1 (en) Cyclic depsipeptide, or derivatives, kallikrein 7 inhibitors, obtained from chondromyces crocatus, method of obtaining and therapeutic uses.
CY1108085T1 (en) Substituted 1,3-bisphenylprop-2-en-1-one derivatives for the production and use thereof
BR0314071A (en) 1,3-Diamino-2-hydroxypropane prodrug derivatives
AR050717A1 (en) PHARMACEUTICAL COMPOSITIONS
TR201910177T4 (en) Fast dissolution formulation containing a cinacalcet HCl.
CO6561830A2 (en) IGE CH3 PEPTIDE VACCINE
AR029825A1 (en) A PHARMACEUTICALLY ACCEPTABLE COMPOSITION INCLUDING CARVEDILOL OR A SALT OF THE SAME PHARMACEUTICALLY ACCEPTABLE, A PROCEDURE FOR THE PRODUCTION OF SUCH COMPOSITION AND USE OF THE SAME
AR036813A1 (en) PHARMACEUTICAL COMPOSITIONS
PA8583501A1 (en) PIRROLIDONE DERIVATIVES AS MAOB INHIBITORS
BRPI0416287A (en) compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for the treatment and / or prevention of diseases that are modulated by accß inhibitors and their use
BRPI0517032A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or preventing diseases and using such compounds
BRPI0409454A (en) compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the treatment and / or prophylaxis of diseases that are associated with the glucagon receptor and their use
NO20084478L (en) Conjugated Lipid Derivatives
NO20070665L (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
AR040441A1 (en) TIOL COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE TO PREPARE IT AND INTERMEDIATE COMPOSITE OF UTILITY IN THIS PROCEDURE
BR112023022755A2 (en) CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY EFFECT FOR KRAS, BUT NOT FOR HRAS AND NRAS
ATE311866T1 (en) USE OF R-ARYLPROPIONIC ACIDS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF DISEASES OF A RHEUMATIC NATURE
AR039664A1 (en) PHARMACEUTICAL COMPOSITION INCLUDED BY A LIPASE AND GLUCOMANAN INHIBITOR
CL2019002020A1 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease.
HUP0302970A2 (en) Use of amino acids for treating pain, process for their preparation and pharmaceutical compositions containing them
BR112013023167A2 (en) method for producing recombinant human factor viii, recombinant human factor viii, pharmaceutical product, use of recombinant human factor viii, method for treating diseases related to decrease, inactivation or absence of factor viii, use of endoprotease spc6 and / or pace4 ai and / or pacesol and proteolytic processing of recombinant human factor viii